Skip to main navigation Skip to search Skip to main content

Characterization of two novel mutations in IL-12R signaling in MSMD patients

  • Elham Alipour Fayez
  • , Zahra Koohini
  • , Zohreh Koohini
  • , Hossein Zamanzadeh
  • , Martin de Boer
  • , Dirk Roos
  • , Shahram Teimourian

Research output: Contribution to journalArticleAcademicpeer-review

72 Downloads (Pure)

Abstract

Mendelian Susceptibility to Mycobacterial Disease (MSMD) is a rare syndrome with infections-among other complications-after Bacillus Calmette-Guerin (BCG) vaccination in children. We focused on the IL-12/IFN-γ pathway to identify new mutations in our patients. This study included 20 patients by vulnerability to mycobacteria and clinical manifestations of severe, recurrent infections. Blood samples were activated with BCG, BCG + IL-12 and BCG + IFN-γ. Cytokine levels were analyzed by ELISA. Measurements of IL-12Rβ1 and IL-12Rβ2 on the surface of peripheral blood mononuclear cells were performed by flow cytometry. To detect genetic defects, next-generation sequencing was performed by Thermo Fisher immunodeficiency panel. Flow cytometry analysis of 20 patients indicated reduction in IL-12R (β1/β2) expression in seven patients who showed incomplete production of IFN-γ by ELISA. In the patient with reduced IL-12 production, IFN-γR and IL-12R (β1/β2) expression levels were normal. Mutation analysis showed three previously reported mutations, two novel mutations in IL-12 R (β1/β2), and one previously reported mutation in IL-12.
Original languageEnglish
JournalPathogens and disease
Volume77
Issue number3
DOIs
Publication statusPublished - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Characterization of two novel mutations in IL-12R signaling in MSMD patients'. Together they form a unique fingerprint.

Cite this